GSK/XenoPort Prep RLS Candidate For Phase III In Neuropathic Pain
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms plan to initiate pivotal trials of XP13512 in neuropathic pain this year after releasing positive Phase III data for restless legs syndrome.
You may also be interested in...
GSK/SkyePharma’s Requip XL Has Mid-December Action Date
Extended-release ropinirole uses Skye’s proprietary GeoMatrix technology to provide steady levels over 24 hours.
GSK Extends RLS Franchise With Gabapentin Prodrug Through XenoPort Deal
XP13512 is in Phase III development for restless legs syndrome and Phase II for neuropathic pain.
Janssen US Net Drug Prices Declined 5.7% in 2020; J&J Pushes Rebate Reform
Janssen's net drug prices declined for the fourth year in a row in 2020, while list prices increased 3.8%, according to the company's drug pricing report.